Article

Subscriber access provided by University of Wollongong Library

On Water: Metal-free Synthesis of Highly Functionalized Benzothiazolylidene from ortho-Haloanilines

Kapil Mohan Saini, Rakesh K. Saunthwal, Shiv Kumar, and Akhilesh K. Verma

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.8b03107 • Publication Date (Web): 31 Jan 2019

Downloaded from http://pubs.acs.org on January 31, 2019

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

On Water: Metal-free Synthesis of Highly Functionalized Benzothiazolylidene from *ortho*-Haloanilines

Kapil Mohan Saini, Rakesh K. Saunthwal, Shiv Kumar and Akhilesh K. Verma*

Synthetic Organic Chemistry Research Laboratory, Department of Chemistry, University of Delhi, Delhi–110007, India

Email: averma@acbr.du.ac.in



Metal-Free
 Mild Condition
 Green Solvent
 Broad Substrate Scope

ABSTRACT: An environmentally benign, transition-metal-free organic base promoted one-pot cascade synthesis of highly functionalized benzo[*d*]thiazol-2(3*H*)-ylidene benzamide in the presence of water has been accomplished by three-component reaction of *ortho*-iodoanilines, acrylates, and aroyl isothiocyanates. The protocol involves the *in situ* generation of thiourea intermediate followed by triethylamine induced intramolecular SN_{Ar} displacement reaction and subsequent Michael addition onto acrylate leads to the formation of benzo[*d*]thiazol-2(3H)-ylidene benzamide. Benzo[*b*]thiazole is also generated in good yields using amidation and intramolecular aromatic nucleophilic substitution chemistry. The control experiments support the proposed mechanistic pathway. Further X-ray crystallographic studies confirm the assigned structures of the fused benzamide.

INTRODUCTION

Heterocyclic processes in nature frequently inspire the organic chemist to discover new organic reactions for the synthesis of biologically active pharmacophores.¹ Among various efforts committed towards the development of bio-active compounds, cascade process ² has appeared as a potent synthetic tool in modern organic chemistry. The evolution of unique five-membered heterocyclic framework is particularly important in drug discovery. In this perspective, the benzothiazolylidene and benzothiazole core reserve privileged structure in medicinal chemistry as antitumor agents, neuronal nicotinic receptor, anti-rotavirus infections, nuclear hormone receptor, anti-infective herbicidal, anti-inflammatory, anti-viral, anticonvulsant, and cardiovascular activity (Figure 1).^{1.4}



Figure 1. Medicinally important thiazolylidene and benzothiazole cores.

Industrial chemical processes mainly emphasis on the use of a metal-catalyst strategy. Recent years have validated great progress in the development of small ring heterocycles using tandem and cascade approaches.⁵ In general, the transition metal catalyst is high- priced and often require a supporting ligand which invents the overall process eco-unfriendly. As a result, the sustainable development of metal-free catalysis is in high demand. Some improvements in the methodology



In past decades Bao,⁸ and Smith III⁹ groups reported the synthesis of *N*-substituted-2aminobenzothiazoles from 2-haloanilines and isothiocyanates using 15 mol% copper (I) in DMSO at 95-115 °C. In 2015, Marcus *et al.* demonstrated DBU promoted synthesis of 2-

iminothiazolidines by employing substituted thioureas and allylic bromides (Scheme 1a).¹⁰ Recently Dethe and co-workers^{11a} developed a facile route for the synthesis of thiazolidine-2imines and thiazolidine-2-ylideneamine using catalytic chiral copper-pybox complex under solvent-free conditions (Scheme 1b). In 2017, the same group reported an improved method for the synthesis of thiazolidine-2-ylideneamines by thiol-yne coupling of propargylamine under solvent-free condition by bond anion relay chemistry.^{11b} In 2015, our group reported a green protocol, for the synthesis of functionalized tetrahydroquinazolines from 2-aminophenylacrylate with excellent chemoselectivity (Scheme 1c).¹² Recently, Patel and co-workers reported an interesting chemistry for the synthesis of quinoline-4(1H)-thiones from aroyl isothiocyanates and o-alkynylanilines by a 6-exo-dig S-cyclization of the in situ generated thiourea followed by rearrangement (Scheme 1d).¹³ Despite novelty and versatility of reported methods, metal-free, sustainable and operationally simple synthetic methods are still in demand. In continuation of our efforts on sustainable approaches for the synthesis of biologically useful molecules,¹⁴ herein we have demonstrated the base-promoted one-pot synthesis of benzo[d]thiazol-2(3H)-ylidene benzamides via amidation followed by intramolecular SNAr displacement and Michael-addition reaction (Scheme 1e).

RESULTS AND DISCUSSION

A successful cascade synthesis of benzothiazolylidene required the catalytic system with high efficiency and cost-effective reagents. With this objective, we started our investigation using 2-iodoaniline **1a**, benzoyl isothiocyanate **2a**, and methyl acrylate **3a** as our model substrates (Table 1). The three component reaction of 2-iodoaniline **1a**, benzoyl isothiocyanate **2a** with **3a** using 10 mol% of bis(triphenylphosphine)palladium chloride and 2.5 equiv of triethylamine in water for 20 h at 100 °C, gave the benzothiazolylidene product **4a** in 70% yield

(entry 1). Switching, the water to polar organic solvents such as DMF and DMSO, did not provide the desired product **4a** (entries 2–3).

	NH ₂ O + Ph NC 1a 2a	S ⁺ CO ₂ Me 3a	catalyst base, solvent temp, time	- S N 4a CO ₂ Me	Ph
entry	catalyst (mol %)	base (equiv)	solvent	T (h) / t (°C)	yield $(\%)^b$ 4a
1	Pd(PPh ₃) ₂ Cl ₂ /10	Et ₃ N / 2.5	H ₂ O	20/100	70
2	$Pd(PPh_3)_2Cl_2/10$	Et ₃ N / 2.5	DMF	20/100	00^c
3	$Pd(PPh_3)_2Cl_2/10$	Et ₃ N / 2.5	DMSO	20/100	00^{c}
4	-	Et ₃ N / 2.5	H_2O	20/90	75
5	-	Et ₃ N / 3.0	H_2O	20/90	85
6	-	Et ₃ N / 3.0	H_2O	24/90	85
7	-	Et ₃ N / 3.0	H_2O	24/70	50
8	-	Et ₃ N / 2.0	H_2O	20/90	60
9	-	Cs ₂ CO ₃ / 2.0	H_2O	24/90	40
10	-	K ₂ CO ₃ /2.0	H_2O	24/90	35
11	-	Na ₂ CO ₃ /2.0	H_2O	24/90	28
12	-	KOH/2.0	H_2O	24/90	00^d
13	-	-	H_2O	24/90	00
14	-	Et ₃ N / 3.0	EtOH	20/90	15^e

 Table 1. Optimization of the Bio-active Benzothiazolylidene^a

^{*a*}Unless otherwise noted all reactions were carried out using 2-iodoaniline **1a** (0.50 mmol), benzoyl isothiocyanate **2a** (0.52 mmol), methyl acrylate **3a** (2.50 mmol), catalyst and base in 2 mL solvent, ^{*b*}Isolated yield. ^{*c*}Only urea intermediate was observed. ^{*d*}Benzo[*d*]thiazole product was observed. ^{*e*}Along with benzo[*d*]thiazole product.

An interesting result was observed when the reaction was carried out in the absence of palladium catalyst; the product 4a was obtained in 75% yield (entry 4). To our delight, the isolated yield was improved to 85% by decreasing the reaction temperature from 100 °C to 90 °C (entry 5). On running the reaction for 24 h, didn't affect the yield of the coupled product 4a (entry 6). The further decrease in reaction temperature afforded the desired product 4a in 50% yield (entry 7). Lowering the amount of Et₃N provided the cyclized product 4a in 60% yield (entry 8). Use of Cs₂CO₃, K₂CO₃, and Na₂CO₃, instead of Et₃N furnished the product 4a in lower yield (entries 9–11). KOH provided the Benzo[d]thiazole product in 40% yield (entry 12). It is noteworthy that no desired product 4a was obtained in the absence of a base (entry 13). Ethanol gave product 4a in 15% yield along with benzo[d]thiazole product (entry 14).

Table 2. Synthesis of Benzothiazolylidene Benzamide











^{*a*}All reactions were carried out using aniline **1** (0.50 mmol), benzoyl isothiocyanate **2** (0.52 mmol), acrylate **3** (2.50 mmol), Et₃N (3.0 equiv) in 2 mL H₂O, ^{*b*}Time 22 h

Having established the optimum reaction conditions, we next studied the substrate scope and generality of the reaction using an eco-friendly approach (Table 2). Reaction of 2iodoaniline 1a, benzoyl isothiocyanate 2a and methyl acrylate 3a proceeded with an inclusive conversion to gave the benzo d thiazol-2(3H)-ylidene benzamide 4a in 85% yield (Table 2, entry 1). Ethyl (**3b**), *n*-butyl (**3c**) and *tert*-butyl (**3d**) acrylates with 2-iodoaniline **1a** and benzoyl isothiocyanate 2a afforded the desired products 4b-d, in 78-84% yields (entries 2-4). The structures of the desired products 4c and 4d were further confirmed by the X-ray crystallographic studies (See SI).¹⁵ N, N-Dimethylacrylamide **3e** and acrylonitrile **3f** were well implemented in the reaction, providing the cyclized products 4e-f in good yield (entries 5–6). Para and meta-substituted benzoyl isothiocyanate 2b-c delivered the products 4g-k, in good yield (entries 7–11). Our methodology was compatible with the combination of electron-rich 2iodo-5-methylaniline 1b and benzoyl isothiocyanate 2a with Michael acceptor olefins 3a-f fruitfully provided the desired products 41-p, in 70-86% yields (entries 12-16). Electrondonating aniline and isothiocyanate furnished the benzothiazolylidene products 4q-t in 77-82% yield (entries 17–20). Electron-deficient 3-chlorobenzoyl isothiocyanate 2d was well tolerated

 in the reaction to provide the cyclized product $4\mathbf{u}$ in good yield (entry 21). Functional groups such as 4-chloro and 4-fluoro substituted 2-iodoanilines afforded the desired product $4\mathbf{v}-\mathbf{z}$, in 65–72% yields (entries 22–26).

Scheme 2. Synthesis of Benzo[d]thiazole



Additionally, we explored the synthesis of benzo[d]thiazolyl using green approach (Scheme 2). The reaction was initiated with 2-iodoaniline **1a**, benzoyl isothiocyanate **2a** using 2.0 equiv. of Et₃N and water as a green solvent at 90 °C for 4 h and the desired *N*-(benzo[d]thiazol-2-yl) benzamide **5a** was observed in 89% yield. As depicted in Scheme 2, 4-methylbenzoyl isothiocyanate was smoothly converted to product **5b** in 90% yield. It is worthy to note, electron-rich 2-iodoanilines provided the cyclized products **5c**-**d**, in 86–88% yields. It was found that the electron-withdrawing -F and -Cl substituted 2-iodoanilines were well tolerated in this reaction, yielded the benzothiazolyl products **5e**-**f** in good yield. X-ray crystal structure also confirmed the structure of product **5e** (See SI).¹⁵

Scheme 3. Mechanistic Control Experiments



Now, our next effort was directed towards the mechanistic studies of the reactions (Scheme 3). The reaction of 2-iodoanilines **1a** with **2b** in water at 90 °C, afforded the urea intermediate **6** (Scheme 3i). This urea adduct **6** was further employed with acrylate using 3.0 equiv of Et₃N in a green solvent, provided the benzothiazolylidene **4j**; however, the simple Michael adduct **7** was not formed (Scheme 3 ii). Benzo[*d*]thiazole **5a** participated well with acrylate **3a** to provide the desired product **4a** (Scheme 3 iii). All the above control experiments suggested that the reaction goes *via* a cascade process.

Scheme 4. Plausible Reaction Pathway



Based on the control experiments and literature studies,¹⁶ we proposed a plausible mechanistic pathway in Scheme 4. The mechanism was initiated by the reaction of *o*-halo anilines 1 with isothiocyanates 2 which leads to the formation of urea intermediate 6. With the support of the base (Et₃N), intramolecular nucleophilic attack of sulphur on the ipso position of iodobenzene occurs. The loss of iodine *via* an aromatic nucleophilic substitution reaction leads to the formation of benzothiazolyl product **5**. The regioselective olefin insertion at benzothiazolyl nitrogen then generates the product **4** *via* a 1, 4-addition step.

CONCLUSIONS

In conclusion, we have developed an environmentally benign; operationally simple, catalystfree cascade approach for the synthesis of highly functionalized benzothiazolylidene benzamide derviatives using mild reaction conditions with excellent regioselectivity in good to excellent yields. *Ortho*-iodoanilines and aroyl isothiocyanates bearing electron-releasing and electronwithdrawing groups successfully provided the desired products in good yields. Water is nonflammable and inexpensive solvent in contrast to other organic solvents, which show the remarkable effect on the yield and rate of the organic reaction *via* hydrophobic interactions. The developed chemistry can be used for the synthesis of benzo[d]thiazolyl derivatives from 2-iodoaniline, benzoyl isothiocyanate through *in situ* formations of *N*-(phenylcarbamothioyl) benzamide and concomitant intramolecular aromatic nucleophilic substitution reaction. We anticipate that this protocol is useful for the synthesis of highly substituted benzothiazole derivatives, which could find further application in the synthesis of the biologically active compound.

EXPERIMENTAL SECTION

General Information and Method. All the reactions were performed in an oven-dried Schlenk flask. Column chromatography was performed using silica gel (mesh 100-200). TLC analysis was performed on commercially prepared 60 F_{254} silica gel plates. Visualization of spots on TLC plate was accomplished with UV light (254 nm) and staining over I₂ chamber. ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) spectra were recorded in CDCl₃ and (CD₃)₂SO.Chemical shifts for carbons are reported in ppm from tetramethylsilane and are referenced to the carbon resonance of the solvent. Data are reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, dd = doublet of doublet, br s = broad singlet), coupling constants in Hertz, and integration. High-resolution mass spectra were recorded with q–TOF electrospray mass spectrometer. All purchased chemicals were used as received. All melting points are uncorrected.

General experimental procedure for green one-pot synthesis of benzo[d]thiazol-2(3H)ylidene benzamides 4a-z: To a solution of *ortho*-haloanilines 1 (0.5 mmol), aroyl isothiocyanates 2 (0.52 mmol) in tap water (2.0 mL), acrylates 3 (2.5 mmol) and Et₃N (3.0

equiv) were added. The reaction was then stirred at 90 °C until TLC revealed complete conversion of the starting material. After the completion of the reactant, the reaction mixture was then allowed to cool and diluted with H_2O and extracted with EtOAc (3X10 mL). The combined organic layers were dried over Na₂SO₄, concentrated under vacuum, and purified by column chromatography using 100–200 mesh size silica gels (hexane) to afford the corresponding product.

Methyl (*E*)-3-(2-(*benzoylimino*)*benzo*[*d*]*thiazol-3*(2*H*)-*yl*) *propanoate* (**4a**). The product was obtained as a off white needles, mp: 140–142 °C (144.5 mg, 85%); ¹H NMR (400 MHz, DMSO-d₆) δ 8.26–8.24 (m, 2H), 7.75 (d, *J* = 8.2 Hz, 1H), 7.60–7.58 (m, 1H), 7.55–7.51 (m, 4H), 7.50–7.46 (m, 1H), 4.80 (t, *J* = 6.6 Hz, 2H), 3.49 (s, 3H), 2.92 (t, *J* = 6.9 Hz, 2H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 174.1, 170.9, 167.2, 136.7, 134.7, 133.7, 132.6, 129.8, 129.6, 129.1, 128.9, 126.2, 123.7, 123.2, 113.0, 52.1, 42.0, 32.1. HRMS (ESI) [M+H]⁺ Calcd for [C₁₈H₁₇N₂O₃S] 341.0960, found 341.0941.

Ethyl (*E*)-*3*-(2-(*benzoylimino*)*benzo*[*d*]*thiazo*1-*3*(2*H*)-*yl*)*propanoate* (**4b**). The product was obtained as a white needles, mp: 75–77 °C (148.7 mg, 84%); ¹H NMR (400 MHz, CDCl₃) δ 8.35–8.33 (m, 2H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.50–7.47 (m, 1H), 7.45–7.38 (m, 4H), 7.25–7.21 (m, 1H), 4.72 (t, *J* = 7.3 Hz, 2H), 4.06 (q, *J* = 7.3 Hz, 2H), 2.94 (t, *J* = 7.3 Hz, 2H), 1.14 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 170.9, 167.0, 136.2, 136.0, 133.3, 131.9, 129.9, 129.4, 128.0, 126.8, 123.7, 122.8, 111.3, 60.9, 41.3, 32.2, 13.8. HRMS (ESI) [M+H]⁺ Calcd for [C₁₉H₁₉N₂O₃S] 355.1116, found 355.1104.

Butyl (*E*)-3-(2-(*benzoylimino*)*benzo*[*d*]*thiazol-3*(2*H*)-*yl*)*propanoate* (**4c**). The product was obtained as a white needles, mp: 69–71 °C (156.6 mg, 82%); ¹H NMR (400 MHz, DMSO–d₆) δ 15

8.22–8.20 (m, 2H), 7.85 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 8.7 Hz, 1H), 7.55–7.44 (m, 4H), 7.32–7.29 (m, 1H), 4.75 (t, J = 6.4 Hz, 2H), 3.82 (t, J = 7.6 Hz, 2H), 2.87 (t, J = 8.2 Hz, 2H), 1.35–1.28 (m, 2H), 1.12–1.03 (m, 2H), 0.69 (t, J = 7.1 Hz, 3H); ¹³C{¹H} NMR (100 MHz, DMSO–d₆) δ 173.6, 170.7, 166.7, 136.2, 136.1, 132.1, 129.1, 128.3, 127.2, 125.7, 124.0, 123.1, 112.5, 64.1, 41.5, 32.1, 29.9, 18.5, 13.5. HRMS (ESI) [M+H]⁺ Calcd for [C₂₁H₂₃N₂O₃S] 383.1429, found 383.1401.

tert-Butyl (*E*)-3-(2-(*benzoylimino*)*benzo*[*d*]*thiazol-3*(2*H*)-*yl*) *propanoate* (**4d**). The product was obtained as a white needles, mp: 133–135 °C (149.0 mg, 78%); ¹H NMR (400 MHz, CDCl₃) δ 8.37–8.35 (m, 2H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.50–7.48 (m, 1H), 7.46–7.42 (m, 4H), 7.28–7.24 (m, 1H), 4.72 (t, *J* = 7.8 Hz, 2H), 2.87 (t, *J* = 8.7 Hz, 2H), 1.37 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 170.1, 167.0, 136.3, 132.0, 129.6, 128.1, 126.6, 123.6, 122.8, 111.3, 81.4, 41.5, 33.5, 27.9, 27.8. HRMS (ESI) [M+H]⁺ Calcd for [C₂₁H₂₃N₂O₃S] 383.1429, found 383.1400.

(*E*)-*N*-(*3*-(*dimethylamino*)-*3*-oxopropyl)benzo[*d*]thiazol-2(3*H*)-ylidene)benzamide (**4e**). The product was obtained as a white needles, mp: 119–121 °C (114.7 mg, 65%); ¹H NMR (400 MHz, CDCl₃) δ 8.34–8.32 (m, 2H), 7.65 (d, *J* = 7.8 Hz, 1H), 7.51–7.47 (m, 2H), 7.45–7.41 (m, 3H), 7.28–7.25 (m, 1H), 4.81 (t, *J* = 7.8 Hz, 2H), 2.93 (t, *J* = 7.3 Hz, 2H), 2.91 (s, 3H), 2.87 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 170.2, 167.3, 136.5, 136.46, 132.2, 129.6, 128.3, 127.2, 126.8, 124.0, 123.0, 111.8, 42.3, 37.3, 35.5, 31.0. HRMS (ESI) [M+H]⁺ Calcd for [C₁₉H₂₀N₃O₂S] 354.1276, found 354.1257.

(*E*)-*N*-(3-(2-cyanoethyl)benzo[d]thiazol-2(3H)-ylidene)benzamide (**4f**). The product was obtained as a white needles, mp: 208–210 $^{\circ}$ C (104.5 mg, 68%); ¹H NMR (400 MHz, CDCl₃) δ 8.33–8.31

(m, 2H), 7.71 (d, J = 7.8 Hz, 1H), 7.56–7.52 (m, 1H), 7.50–7.43 (m, 4H), 7.36–7.32 (m, 1H), 4.77 (t, J = 7.3 Hz, 2H), 3.08 (t, J = 7.3 Hz, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.9, 167.3, 140.4, 135.9, 135.6, 132.3, 129.5, 128.2, 127.3, 126.6, 124.4, 123.3, 116.9, 110.8, 41.1, 16.1. HRMS (ESI) [M+H]⁺ Calcd for [C₁₇H₁₄N₃OS] 308.0858, found 308.0856.

Methyl (*E*)-3-(2-((4-methylbenzoyl)imino)benzo[*d*]thiazol-3(2*H*)-yl)propanoate (**4g**). The product was obtained as a white needles, mp: 146–148 °C (141.6 mg, 80%); ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 7.8 Hz, 2H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.39–7.38 (m, 2H), 7.24–7.18 (m, 3H), 4.70 (t, *J* = 7.3 Hz, 2H), 3.59 (s, 3H), 2.92 (t, *J* = 7.3 Hz, 2H), 2.35 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 171.6, 167.2, 142.7, 136.3, 133.8, 130.3, 129.7, 129.0, 127.0, 126.96, 123.9, 123.1, 111.4, 52.2, 41.5, 32.1, 21.8. HRMS (ESI) [M+H]⁺ Calcd for [C₁₉H₁₉N₂O₃S] 355.1116, found 355.1108.

Methyl (E)-3-(2-((3-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4h**). The product was obtained as a white needles, mp: 90–92 °C (136.3 mg, 77%); ¹H NMR (400 MHz, CDCl₃) δ 8.15–8.14 (m, 2H), 7.64 (d, J = 7.8 Hz, 1H), 7.42 (d, J = 4.1 Hz, 2H), 7.33–7.31 (m, 2H), 7.28–7.24 (m, 1H), 4.76 (t, J = 7.1 Hz, 2H), 3.63 (s, 3H), 2.96 (t, J = 6.9 Hz, 2H), 2.41 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.0, 171.3, 167.0, 137.6, 136.2, 136.1, 132.7, 130.0, 127.9, 127.2, 126.8, 126.7, 123.7, 122.9, 111.3, 52.0, 41.3, 31.9, 21.3. HRMS (ESI) [M+H]⁺ Calcd for [C₁₉H₁₉N₂O₃S] 355.1116, found 355.1118.

Ethyl (*E*)-3-(2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4i**). The product was obtained as a white needles, mp: 117–119 °C (143.9 mg, 78%); ¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, *J* = 8.2 Hz, 2H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.44–7.42 (m, 2H), 7.28–7.23(m, 3H), 4.74 (t,

 $J = 6.9 \text{ Hz}, 2\text{H}, 4.08 \text{ (q, } J = 7.3 \text{ Hz}, 2\text{H}), 2.96 \text{ (t, } J = 6.9 \text{ Hz}, 2\text{H}), 2.40 \text{ (s, } 3\text{H}), 1.17 \text{ (t, } J = 7.3 \text{ Hz}, 3\text{H}); {}^{13}\text{C}\{{}^{1}\text{H}\} \text{ NMR (100 MHz, CDCl}_{3}) \delta 175.0, 171.2, 167.1, 142.6, 136.3, 133.8, 129.7, 129.68, 129.0, 128.1, 127.0, 123.9, 123.0, 111.5, 61.2, 41.5, 32.4, 21.7, 14.1. \text{ HRMS (ESI) [M+H]}^+ \text{Calcd for [C}_{20}\text{H}_{21}\text{N}_{2}\text{O}_{3}\text{S}] 369.1273, found 369.1273.}$

Butyl (*E*)-3-(2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4j**). The product was obtained as a white needles, mp: 166–168 °C (173.1 mg, 87%); ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 7.8 Hz, 2H), 7.63 (d, *J* = 7.8 Hz, 1H), 7.42–7.41 (m, 2H), 7.26–7.22 (m, 3H), 4.72 (t, *J* = 7.3 Hz, 2H), 4.02 (t, *J* = 6.9 Hz, 2H), 2.94 (t, *J* = 7.3 Hz, 2H), 2.38 (s, 3H), 1.53–1.46 (m, 2H), 1.30–1.21 (m, 2H), 0.85 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 171.0, 166.8, 142.4, 136.1, 133.6, 129.5, 128.7, 126.8, 126.7, 123.6, 122.8, 111.3, 64.9, 41.4, 32.2, 30.3, 21.5, 18.9, 13.5. HRMS (ESI) [M+H]⁺ Calcd for [C₂₂H₂₅N₂O₃S] 397.1586, found 397.1578.

tert-Butyl (*E*)-3-(2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4k**). The product was obtained as a white needles, mp: 139–141 °C (150.5 mg, 76%); ¹H NMR (400 MHz, CDCl₃) δ 8.24 (d, *J* = 7.8 Hz, 2H), 7.62 (d, *J* = 8.0 Hz, 1H), 7.41–7.38 (m, 2H), 7.26–7.22 (m, 3H), 4.68 (t, *J* = 6.9 Hz, 2H), 2.85 (t, *J* = 7.1 Hz, 2H), 2.38 (s, 3H), 1.37 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.7, 170.1, 166.6, 142.3, 136.1, 133.6, 129.4, 128.7, 126.7, 126.6, 123.5, 122.7, 111.3, 81.2, 41.4, 33.4, 27.8, 21.5. HRMS (ESI) [M+H]⁺ Calcd for [C₂₂H₂₅N₂O₃S] 397.1586, found 397.1577.

 Methyl (*E*)-3-(2-(*benzoylimino*)-5-*methylbenzo*[*d*]*thiazo*l-3(2*H*)-*y*l)*propanoate* (**4**). The product was obtained as a white needles, mp: 125–127 °C (152.2 mg, 86%); ¹H NMR (400 MHz, CDCl₃) δ 8.37–8.35 (m, 2H), 7.55–7.44 (m, 4H), 7.24 (s, 1H), 7.11 (d, *J* = 7.8 Hz, 1H), 4.75 (t, *J* = 7.3 Hz, 2H), 3.67 (s, 3H), 2.97 (t, *J* = 7.8 Hz, 2H), 2.48 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 171.3, 167.5, 137.4, 136.3, 136.2, 133.3, 131.9, 130.0, 129.4, 128.0, 123.6, 122.6, 111.6, 52.0, 41.2, 31.9, 21.7. HRMS (ESI) [M+H]⁺ Calcd for [C₁₉H₁₉N₂O₃S] 355.1116, found 355.1112.

Ethyl (*E*)-*3*-(2-(*benzoylimino*)-5-*methylbenzo*[*d*]*thiazo*I-*3*(2*H*)-*y*I)*propanoate* (**4m**). The product was obtained as a white needles, mp: 141–143 °C (156.4 mg, 85%); ¹H NMR (400 MHz, CDCl₃) δ 8.37–8.34 (m, 2H), 7.54–7.51 (m, 2H), 7.49–7.44 (m, 2H), 7.24 (s, 1H), 7.10 (d, *J* = 7.8 Hz, 1H), 4.74 (t, *J* = 6.9 Hz, 2H), 4.11 (q, *J* = 7.3 Hz, 2H), 2.95 (t, *J* = 7.3 Hz, 2H), 2.47 (s, 3H), 1.19 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.7, 170.9, 167.4, 137.3, 136.3, 136.2, 131.8, 129.4, 128.7, 128.0, 125.0, 123.5, 122.5, 111.7, 61.0, 41.3, 32.2, 21.7, 13.9. HRMS (ESI) [M+H]⁺ Calcd for [C₂₀H₂₁N₂O₃S] 369.1273, found 369.1256.

Butyl (*E*)-*3*-(2-(*benzoylimino*)-5-*methylbenzo*[*d*]*thiazo*1-*3*(2*H*)-*y*1)*propanoate* (**4n**). The product was obtained as a white needles, mp: 86–88 °C (164.4 mg, 83%); ¹H NMR (400 MHz, CDCl₃) δ 8.36–8.34 (m, 2H), 7.55–7.49 (m, 2H), 7.47–7.43 (m, 2H), 7.24 (s, 1H), 7.10 (d, *J* = 7.3 Hz, 1H), 4.74 (t, *J* = 7.3 Hz, 2H), 4.06 (t, *J* = 6.4 Hz, 2H), 2.95 (t, *J* = 7.3 Hz, 2H), 2.48 (s, 3H), 1.57–1.50 (m, 2H), 1.34–1.24 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 171.1, 167.5, 137.4, 136.4, 136.3, 131.9, 129.5, 128.0, 125.1, 125.05, 123.6, 122.6, 111.7, 111.68, 65.0, 41.4, 32.3, 30.4, 21.7, 19.0, 13.6. HRMS (ESI) [M+H]⁺ Calcd for [C₂₂H₂₅N₂O₃S] 397.1586, found 397.1570.

tert-Butyl(E)-3-(2-(benzoylimino)-5-methylbenzo[d]thiazol-3(2H)-yl)propanoate (40). The product was obtained as a white needles, mp: 138–140 °C (156.5 mg, 79%); ¹H NMR (400 MHz, CDCl₃) δ 8.37–8.35 (m, 2H), 7.54–7.49 (m, 2H), 7.47–7.43 (m, 2H), 7.24 (s, 1H), 7.09 (d, *J* = 8.2 Hz, 1H), 4.71 (t, *J* = 7.3 Hz, 2H), 2.86 (t, *J* = 7.3 Hz, 2H), 2.47 (s, 3H), 1.39 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 170.2, 167.4, 137.3, 136.4, 136.36, 131.8, 129.5, 128.0, 125.0, 124.9, 123.6, 122.5, 111.9, 111.8, 81.4, 41.5, 33.6, 27.9, 21.7.HRMS (ESI) [M+H]⁺ Calcd for [C₂₂H₂₅N₂O₃S] 397.1586, found 397.1565.

(*E*)-*N*-(*3*-(2-cyanoethyl)-5-methylbenzo[*d*]thiazol-2(3*H*)-ylidene)benzamide (**4p**). The product was obtained as a white needles, mp: 194–196 °C (112.3 mg, 70%); ¹H NMR (400 MHz, CDCl₃) δ 8.29–8.27 (m, 2H), 7.54–7.48 (m, 2H), 7.46–7.42 (m, 2H), 7.19 (s, 1H), 7.12 (d, *J* = 7.8 Hz, 1H), 4.71 (t, *J* = 7.3 Hz, 2H), 3.03 (t, *J* = 7.3 Hz, 2H), 2.47 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.8, 167.5, 137.8, 135.7, 132.6, 129.9, 128.8, 128.6, 127.7, 126.0, 125.1, 123.3, 122.4, 116.9, 111.6, 40.9, 22.1, 16.0. HRMS (ESI) [M+H]⁺ Calcd for [C₁₈H₁₆N₃OS] 322.1014, found 322.1000.

Ethyl (*E*)-3-(5-*methyl*-2-((4-*methylbenzoyl*)*imino*)*benzo*[*d*]*thiazo*l-3(2*H*)-*yl*)*propanoate* (**4q**). The product was obtained as a white needles, mp: 151–153 °C (156.6 mg, 82%); ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, *J* = 8.2 Hz, 2H), 7.49 (d, *J* = 7.8 Hz, 1H), 7.24–7.19 (m, 3H), 7.06 (d, *J* = 8.2 Hz, 1H), 4.69 (t, *J* = 7.6 Hz, 2H), 4.09 (q, *J* = 7.3 Hz, 2H), 2.92 (t, *J* = 7.3 Hz, 2H), 2.45 (s, 3H), 2.38 (s, 3H), 1.17 (t, *J* = 6.9 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.6, 170.9, 167.1, 142.2, 137.2, 136.2, 133.7, 129.4, 128.7, 124.9, 123.5, 122.4, 111.6, 60.9, 41.2, 32.2, 21.6, 21.5, 13.9; HRMS (ESI) [M+H]⁺ Calcd for [C₂₁H₂₃N₂O₃S] 383.1429, found 383.1400.

Butyl (E)-3-(5-methyl-2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4r**). The product was obtained as a white needles, mp: 166–168 °C (164.1 mg, 80%); ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J = 7.8 Hz, 2H), 7.50 (d, J = 7.8 Hz, 1H), 7.24–7.19 (m, 3H), 7.06 (d, J = 8.2 Hz, 1H), 4.70 (t, J = 7.3 Hz, 2H), 4.04 (t, J = 6.9 Hz, 2H), 2.92 (t, J = 7.3 Hz, 2H), 2.45 (s, 3H), 2.39 (s, 3H), 1.55–1.48 (m, 2H), 1.32–1.23 (m, 2H), 0.86 (t, J = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.7, 171.0, 167.1, 142.3, 137.2, 136.3, 133.7, 129.5, 128.7, 124.9, 123.6, 122.5, 111.6, 64.9, 41.3, 32.2, 30.3, 21.7, 21.6, 18.9, 13.6; HRMS (ESI) [M+H]⁺ Calcd for [C₂₃H₂₇N₂O₃S] 411.1742, found 411.1731.

tert-Butyl (*E*)-3-(5-*methyl*-2-((4-*methylbenzoyl*)*imino*)*benzo*[*d*] *thiazol*-3(2*H*)-*yl*)*propanoate* (**4s**). The product was obtained as a white needles, mp: 181–183 °C (157.9 mg, 77%); ¹H NMR (400 MHz, CDCl₃) δ 8.26 (d, *J* = 8.2 Hz, 2H), 7.55 (d, *J* = 9.2Hz, 1H), 7.26–7.25 (m, 3H), 7.11 (d, *J* = 9.2 Hz, 1H), 4.73 (t, *J* = 7.8 Hz, 2H), 2.87 (t, *J* = 7.8 Hz, 2H), 2.50 (s, 3H), 2.42 (s, 3H), 1.40 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.9, 170.3, 167.3, 142.4, 137.3, 136.5, 133.9, 129.7, 128.9, 128.8, 125.1, 123.8, 122.7, 111.9, 81.5, 41.5, 33.6, 28.0, 21.7, 21.69; HRMS (ESI) [M+H]⁺ Calcd for [C₂₃H₂₇N₂O₃S] 411.1742, found 411.1736.

Ethyl (*E*)-*3*-(*5*-*methyl*-2-((*3*-*methylbenzoyl*)*imino*)*benzo*[*d*]*thiazo*[-*3*(2*H*)-*yl*)*propanoate* (**4t**). The product was obtained as a white needles, mp: 145–147 °C (149.0 mg, 78%); ¹H NMR (400 MHz, CDCl₃) δ 8.04–8.02 (m, 2H), 7.38–7.35 (m, 1H), 7.23–7.18 (m, 2H), 7.08 (s, 1H), 6.95–6.93 (m, 1H), 4.58 (t, *J* = 6.9 Hz, 2H), 3.97 (q, *J* = 7.3 Hz, 2H), 2.81 (t, *J* = 7.8 Hz, 2H), 2.32 (s, 3H), 2.30 (s, 3H), 1.06 (t, *J* = 7.8 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 174.6, 170.7, 167.1, 137.4, 137.0, 136.1, 136.0, 132.4, 129.8, 127.7, 126.4, 124.8, 123.4, 122.2, 111.5, 60.7, 41.1, 32.1, 21.5, 21.2, 13.8; HRMS (ESI) [M+H]⁺ Calcd for [C₂₁H₂₃N₂O₃S] 383.1429, found 383.1419.

ACS Paragon Plus Environment

Ethyl (E)-3-(2-((3-chlorobenzoyl)imino)-5-methylbenzo[d]thiazol-3(2H)-yl)propanoate (**4u**). The product was obtained as a white needles, mp: 133–135 °C (158.8 mg, 79%); ¹H NMR (400 MHz, CDCl₃) δ 8.31 (s, 1H), 8.22 (d, J = 6.2Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H), 7.49–7.47 (m, 1H), 7.41–7.37 (m, 1H), 7.27 (s, 1H), 7.14 (d, J = 8.3 Hz, 1H), 4.77 (t, J = 7.3 Hz, 2H), 4.13 (q, J = 7.3 Hz, 2H), 2.96 (t, J = 7.3 Hz, 2H), 2.50 (s, 3H), 1.21 (t, J = 6.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 173.5, 170.9, 167.9, 138.3, 137.6, 136.3, 134.2, 131.8, 129.6, 129.4, 127.6, 125.3, 123.6, 122.7, 111.9, 61.1, 41.5, 32.4, 21.8, 14.0; HRMS (ESI) [M+H]⁺ Calcd for [C₂₀H₂₀ClN₂O₃S] 403.0883, found 403.0858.

Ethyl (*E*)-*3*-(2-(*benzoylimino*)-6-*chlorobenzo*[*d*]*thiazo*l-*3*(2*H*)-*y*l)*propanoate* (**4v**). The product was obtained as a white needles, mp: 123–125°C (136.1 mg, 70%); ¹H NMR (400 MHz, CDCl₃) δ 8.34 (d, *J* = 7.8 Hz, 2H), 7.66 (s, 1H), 7.56–7.52 (m, 1H), 7.49–7.45 (m, 2H), 7.43–7.42 (m, 2H), 4.74 (t, *J* = 6.9 Hz, 2H), 4.10 (q, *J* = 7.3 Hz, 2H), 2.99 (t, *J* = 7.3 Hz, 2H), 1.19 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 171.1, 167.1, 136.1, 135.1, 132.3, 129.7, 129.5, 128.5, 128.3, 127.4, 122.8, 112.6, 61.3, 41.9, 32.3, 14.1; HRMS (ESI) [M+H]⁺ Calcd for [C₁₉H₁₈ClN₂O₃S] 389.0727, found 389.0723.

Butyl (*E*)-3-(2-(*benzoylimino*)-6-*chlorobenzo*[*d*]*thiazol-3*(2*H*)-*yl*)*propanoate* (**4w**). The product was obtained as a white needles, mp: 78–80°C (135.5 mg, 65%); ¹H NMR (400 MHz, CDCl₃) δ 8.34 (d, *J* = 8.7 Hz, 2H), 7.65 (s, 1H), 7.56–7.52 (m, 1H), 7.48–7.45 (m, 2H), 7.42–7.41 (m, 2H), 4.73 (t, *J* = 6.6 Hz, 2H), 4.04 (t, *J* = 6.4 Hz, 2H), 2.99 (t, *J* = 6.6 Hz, 2H), 1.56–1.49 (m, 2H), 1.33–1.24 (m, 2H), 0.87 (t, *J* = 7.3 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 171.2, 167.1, 136.1, 135.1, 132.3, 129.7, 129.5, 128.5, 128.3, 127.4, 122.7, 112.6, 65.2, 41.9, 32.4, 30.5, 19.1, 13.7; HRMS (ESI) [M+H]⁺ Calcd for [C₂₁H₂₂ClN₂O₃S] 417.1040, found 417.1048.

Ethyl (*E*)-3-(6-chloro-2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4x**). The product was obtained as a white needles, mp: 135–137 °C (145.0 mg, 72%); ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.2 Hz, 2H), 7.63 (s, 1H), 7.39 (s, 2H), 7.25 (d, *J* = 7.3 Hz, 2H), 4.71 (t, *J* = 6.9 Hz, 2H), 4.09 (q, *J* = 7.3 Hz, 2H), 2.97 (t, *J* = 6.9 Hz, 2H), 2.41 (s, 3H), 1.18 (t, *J* = 7.6 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 171.1, 166.8, 142.9, 135.1, 133.5, 129.7, 129.4, 129.0, 128.5, 127.3, 122.7, 112.5, 61.3, 41.8, 32.3, 21.8, 14.1; HRMS (ESI) [M+H]⁺ Calcd for [C₂₀H₂₀ClN₂O₃S] 403.0883, found 403.0877.

Butyl (E)-3-(6-chloro-2-((4-methylbenzoyl)imino)benzo[d]thiazol-3(2H)-yl)propanoate (**4y**). The product was obtained as a white needles, mp: 82–84 °C (148.6 mg, 69%); ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 7.8 Hz, 2H), 7.60 (s, 1H), 7.37–7.36(m, 2H), 7.22 (d, *J* = 8.2 Hz, 2H), 4.68 (t, *J* = 7.1 Hz, 2H), 4.02 (t, *J* = 6.4 Hz, 2H), 2.95 (t, *J* = 6.9 Hz, 2H), 2.39 (s, 3H), 1.53–1.46 (m, 2H), 1.28–1.23 (m, 2H), 0.85 (t, *J* = 7.6 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 171.3, 166.8, 142.9, 135.1, 133.5, 129.7, 129.4, 129.0, 128.5, 127.3, 122.7, 112.5, 65.2, 41.9, 32.3, 30.5, 21.8, 19.1, 13.8; HRMS (ESI) [M+H]⁺ Calcd for [C₂₂H₂₄ClN₂O₃S] 431.1196, found 431.1205.

(*E*)-*N*-(3-(2-cyanoethyl)-6-fluorobenzo[d]thiazol-2(3H)-ylidene)benzamide (**4z**). The product was obtained as a white needles, mp: 170–172 °C (110.5 mg, 68%); ¹H NMR (400 MHz, DMSO-d₆) δ 8.27–8.25 (m, 2H), 7.90–7.86 (m, 2H), 7.60–7.56 (m, 1H), 7.52–7.49 (m, 3H), 7.44–7.39 (m, 1H), 4.83 (t, *J* = 6.9 Hz, 2H), 3.17 (t, *J* = 6.2 Hz, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 175.1, 167.3, 159.7 (d, *J* = 245.6 Hz, 1C), 135.8, 132.6, 132.1, 129.6, 128.4, 116.9, 115.2 (d, *J* = 24.1

Hz, 1C), 111.8 (d, J = 9.6 Hz, 1C), 110.4 (d, J = 26.0 Hz, 1C), 41.6, 16.3. HRMS (ESI) [M+H]⁺ Calcd for [C₁₇H₁₃FN₃OS] 326.0763, found 326.0762.

General experimental procedure for green one-pot synthesis of benzo[*d*]thiazolyl 5a-f: To a solution of *ortho*-haloanilines 1 (0.5 mmol), aroyl isothiocyanates 2 (0.52 mmol) in tap water (2.0 mL) Et₃N (2.0 equiv) was added. The reaction was then stirred at 90 °C until TLC revealed complete conversion of the starting material. After the completion of the reactant, the reaction mixture was then allowed to cool and diluted with H₂O and extracted with EtOAc (3X10 mL). The combined organic layers were dried over Na₂SO₄, concentrated under vacuum, and purified by column chromatography using 100–200 mesh size silica gels (hexane) to afford the corresponding product.

N-(benzo[d]thiazol-2-yl)benzamide (**5a**). The product was obtained as a white needles, mp: 165– 167 °C (113.1mg, 89%); ¹H NMR (400 MHz, CDCl₃) δ 12.10 (br s, 1H), 8.02–8.00 (m, 2H), 7.83 (d, *J* = 7.8 Hz, 1H), 7.55–7.51 (m, 1H), 7.40–7.36 (m, 2H), 7.28–7.24 (m, 1H), 7.21–7.17 (m, 1H), 7.10–7.08 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.2, 160.0, 147.6, 133.0, 132.0, 131.8, 128.9, 128.0, 126.0, 124.0, 121.3, 120.6. HRMS (ESI) [M+H]⁺ Calcd for [C₁₄H₁₁N₂OS] 255.0592, found 255.0593.

N-(Benzo[d]thiazol-2-yl)-4-methylbenzamide (**5b**). The product was obtained as a white needles, mp: 180–182 °C (120.6 mg, 90%); ¹H NMR (400 MHz, CDCl₃) δ 11.73 (br s, 1H), 7.89 (d, *J* = 8.8 Hz, 2H), 7.83–7.80 (m, 1H), 7.28–7.17 (m, 5H), 2.36 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.1, 160.0, 147.9, 143.9, 132.0, 129.7, 129.3, 128.1, 126.0, 123.9, 121.4, 120.8, 21.7. HRMS (ESI) Calcd for [M+H]⁺ Calcd for [C₁₅H₁₃N₂OS] 269.0749, found 269.0750.

N-(*5-methylbenzo*[*d*]*thiazo*[-2-*y*]*benzamide* (**5c**). The product was obtained as a white needles, mp: 195–197 °C (117.9 mg, 88%); ¹H NMR (400 MHz, CDCl₃) δ 12.47 (br s, 1H), 8.00 (d, *J* = 8.6 Hz, 2H), 7.66 (d, *J* = 8.6 Hz, 1H), 7.52 (t, *J* = 6.8 Hz, 1H), 7.37 (t, *J* = 7.7 Hz, 2H), 7.05 (d, *J* = 7.7 Hz, 1H), 6.64 (s, 1H), 2.18 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.4, 160.4, 147.7, 135.9, 132.8, 132.3, 128.9, 128.5, 128.2, 128.0, 127.3, 125.4, 120.7, 21.3. HRMS (ESI) [M+H]⁺ Calcd for [C₁₅H₁₃N₂OS] 269.0749, found 269.0734.

3-Methyl-N-(5-methylbenzo[d]thiazol-2-yl)benzamide (**5d**). The product was obtained as a white needles, mp: 212–214 °C (114.3 mg, 81%); ¹H NMR (400 MHz, CDCl₃) δ 12.30 (br s, 1H), 7.74 (d, *J*= 7.8 Hz, 1H), 7.72–7.68 (m, 3H), 7.44–7.37 (m, 2H), 6.86–6.83 (m, 1H), 2.42 (s, 3H), 2.34 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.9, 159.9, 139.4, 139.1, 138.9, 138.86, 134.5, 131.3, 130.0, 129.0, 128.5, 128.2, 124.6, 21.3, 20.98. HRMS (ESI) [M+H]⁺ Calcd for [C₁₆H₁₅N₂OS] 283.0905, found 283.0890.

N-(6-fluorobenzo[d]thiazol-2-yl)benzamide (**5e**).The product was obtained as a white needles, mp: 191–193 °C (112.8 mg, 83%); ¹H NMR (400 MHz, CDCl₃) δ 12.04 (br s, 1H), 8.04 (d, *J* = 8.8 Hz, 2H), 7.62–7.56 (m, 1H), 7.53–7.49 (m, 1H), 7.46–7.42 (m, 2H), 7.18–7.14 (m, 1H), 7.01–6.96 (m, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.0, 159.8, 159.5 (d, *J* = 237.7 Hz, 1C), 143.9, 133.2, 132.7 (d, *J* = 10.5 Hz, 1C), 131.7, 130.0, 129.0, 128.0, 121.3, 114.5 (d, *J* = 24.9 Hz, 1C), 107.8 (d, *J* = 4.8 Hz, 1C), 107.5 (d, *J* = 3.8 Hz, 1C). HRMS (ESI) [M+H]⁺ Calcd for [C₁₄H₁₀FN₂OS] 273.0498, found 273.0500.

N-(6-Chlorobenzo[d]thiazol-2-yl)benzamide (**5f**). The product was obtained as a white needles, mp: 223–225 °C (112.3 mg, 78%); ¹H NMR (400 MHz, CDCl₃) δ 10.99 (br s, 1H), 8.13 (s, 1H),

8.00 (d, J = 7.3 Hz, 2H), 7.64–7.61 (m, 1H), 7.57–7.55 (m, 1H), 7.52–7.48 (m, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 165.6, 161.4, 150.3, 133.5, 132.2, 131.5, 129.2, 127.8, 123.3, 120.9, 119.2. HRMS (ESI) [M+H]⁺ Calcd for [C₁₄H₁₀ClN₂OS] 289.0202, found 289.0190.

N-((2-iodophenyl)carbamothioyl)-4-methylbenzamide (**6**). The product was obtained as an off white needles, mp: 160–162 °C (188.6 mg, 95%); ¹H NMR (400 MHz, CDCl₃) δ 12.38 (s, 1H), 9.22 (s, 1H), 7.90–7.86 (m, 2H), 7.81–7.79 (m, 2H), 7.40 (t, *J* = 7.3 Hz, 1H), 7.31 (d, *J* = 7.3 Hz, 2H), 7.03–6.99 (m, 1H), 2.42 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 179.7, 166.6, 144.8, 139.7, 139.3, 129.7, 128.8, 128.4, 127.8, 127.6, 127.3, 95.5, 21.6; HRMS (ESI) [M+H]⁺ Calcd for [C₁₅H₁₄IN₂OS] 396.9872, found 396.9880.

Supporting Information Available: The Supporting Information is available free of charge on the ACS Publications website at DOI: .

¹ H, ¹³C{¹H} and HRMS spectra of synthesized compounds and XRay data (PDF)

X-ray crystallographic data of compounds 4c, 4d, and 5e (CIF).

AUTHOR INFORMATION

Corresponding Author

*E-mail: averma@acbr.du.ac.in.

ORCID

Akhilesh K. Verma: 0000-0001-7626-5003

Notes

The authors declare no competing financial interest.

Acknowledgement: We gratefully acknowledge the DST-SERB and CSIR for financial support and USIC, the University of Delhi for providing instrumentation facilities. K.M.S., R.K.S. and S.K. are thankful to CSIR for fellowship.

References

- (1) (a) Barreca, M. L.;Clercq, E. D. Design, synthesis, structure–activity relationships, and molecular modeling studies of 2,3-Diaryl-1,3-thiazolidin-4-ones as potent anti-HIV agents. *J. Med. Chem.* 2002, 45, 5410–5413. (b) Goel, B.; Kumar, A. 2-Substituted-3-(4bromo-2-carboxyphenyl)-5-methyl-4-thiazolidinones as potential anti-inflammatory agents. *Eur. J. Med. Chem.* 1999, 34, 265–269. (c) Verma, A.; Saraf, S. K. 4-Thiazolidinone – a biologically active scaffold. *Eur. J. Med. Chem.* 2008, 43, 897–905.
- (2) (a) Lu, L. Q.; Chen J. R.; Xiaow. J. Development of cascade reactions for the concise construction of diverse heterocyclic architectures. *Acc. Chem. Res.* 2012, *45*, 1278–1293.
 (b) Barluenga, J.; Rodrguez, F; Fananas, F. J. Recent advances in the synthesis of indole and quinoline derivatives through cascade reactions. *Chem. Asian J.* 2009, *4*, 1036–1048.
 (c) Wang, B. Q.; Zhang, C. H.; Tian, X. X.; Lin, J.; Yan, S. J. Cascade reaction of isatins with 1,1-enediamines: synthesis of multisubstituted quinoline-4-carboxamides. *Org. Lett.* 2018, *20*, 660–663. (d) Zhou, B.; Wu, Z.; Ma, D.; Ji, X.; and Zhang, Y. Synthesis of indoles through palladium-catalyzed three-component reaction of aryl iodides, alkynes, and diaziridinone. *Org. Lett.* 2018, *20*, 6440–6443. (e) Chennapuram, M.; Owolabi, I. A.; Seki, C.; Okuyama, Y.; Kwon, E.; Uwai, K.; Tokiwa, M.; Takeshita, M.; Nakano, H. New hybrid-type squaramide-fused amino alcohol organocatalyst for enantioselective

domino michael addition/cyclization reaction of oxoindolines with cyclic 1,3-diketones. ACS Omega 2018, 3, 11718–11726. (f) Xia, Y.; Zhang, Y.; Wang, J. Catalytic cascade reactions involving metal carbene migratory insertion. ACS Catal. 2013, 3, 2586–2598.
(g) Singh, S.; Samineni, R.; Pabbaraja, S.; Mehta, G. Nitromethane as a carbanion source for domino benzoannulation with ynones: one-pot synthesis of polyfunctional naphthalenes and a total synthesis of macarpine. Angew. Chem. Int. Ed. 2018, 57, DOI: 10.1002/anie.201810652.

- (3) (a) Yoshida, M.; Hayakawa, I.; Hayashi, N.; Agatsuma, T.; Tanzawa, Y. F.; Iwasaki, S.; Koyama, K.; Furukawa, H.; Kurakatad S.; Sugano, Y. Synthesis and biological evaluation of benzothiazole derivatives as potent antitumor agents. *Bioorg. Med. Chem. Lett.* 2005, *15*, 3328–3332 (b) Barreca, M. L.; Chimirri, A.; Luca, L. D.; Monforte, A. M.; Monforte, P.; Rao, A.; Zappalà, M.; Balzarini, J.; Clercq, E. D.; Pannecouque, C.; Witvrouw, M. Discovery of 2,3-diaryl-1,3-thiazolidin-4-ones as potent anti-HIV-1 agents. *Bioorg. Med. Chem. Lett.* 2001, *11*, 1793–1796. (c) Nagar, S.; Singh, H. H.;Sinha, J. N.; Parmar, S. S. Some anticonvulsant and cardiovascular effects of substituted thiazolidones. *J. Med. Chem.* 1973, *16*, 178–180.
- (4) Chen, C. Y.; Barve, I. J.; Sun, C. M. One-pot three-component synthesis of 2-imino-1,3thiazolines on soluble ionic liquid support. *ACS Comb. Sci.* **2016**, *18*, 638–643.
- (5) (a) Saunthwal, R. K.; Danodia, A. K.; Saini, K. M.; Verma, A. K. Ag(I)-catalyzed cycloisomerization reactions: synthesis of substituted phenanthrenes and naphthothiophenes. *Org. Biomol. Chem.* 2017, *15*, 6934–6942. (b) Patel, M.; Saunthwal, R. K.; Verma, A. K. Base-mediated hydroamination of alkynes. *Acc. Chem. Res.*, 2017, *50*, 240–254 and references cited therein. (c) Wang, B.; Sun, S.; Yu, J.T.; Jiang, Y.; 28

The Journal of Organic Chemistry

1	
r	
Z	
3	
4	
ŕ	
5	
6	
7	
/	
8	
a	
10	
11	
10	
12	
13	
14	
1 -	
15	
16	
17	
1/	
18	
19	
20	
20	
21	
22	
23	
24	
25	
25	
26	
27	
20	
20	
29	
30	
21	
31	
32	
22	
22	
34	
35	
20	
36	
37	
28	
20	
39	
40	
11	
41	
42	
43	
44	
45	
16	
40	
47	
48	
10	
49	
50	
51	
51	
52	
53	
- J J	
54	
55	
56	
20	
57	
58	
50	
59	
60	

Cheng, J. Palladium-catalyzed multi-component reactions of *o*-alkynylanilines, aryl iodides, and CO₂ toward 3, 3-diaryl 2, 4-quinolinediones *Org. Lett.* 2017, *19*, 4319–4322.
(6) (a) Cuzzocrea, S.; Zingarelli, B.; Paul, H.; Salzman, A. L.; Szabo, C. Antiinflammatory effects of mercaptoethylguanidine, a combined inhibitor of nitric oxide synthase and peroxynitrite scavenger, in carrageenan-induced models of inflammation. *Free Rad.Biol. Med.*, 1998, *24*, 450–459.(b) Wang, J.;Peng, F.;Jiang J.; Lu, Z.;Wang, L.; Bai, J.;Pan, Y.Synthesis of *N*-benzothiazol-2-yl-amides by a copper-catalyzed intramolecular cyclization process. *Tetrahedron Lett.* 2008, *49*, 467–470. (c) Wanga, J.;Zong, Y. X.;Wanga, X, -C.; Hua, Y. L.; Yue, G. R. Synthesis of *N*-benzothiazol-2-yl-amides by Pd-catalyzed C(sp2)-H functionalization. *Chinese Chem. Lett.* 2015, *26*, 1376–1380.

- (7) (a) Craig, R. A.; Connor, N. R. O; Goldberg, A. F. G.; Stoltz, B. M. Stereoselective lewis acid mediated (3+2) cycloadditions of *N-H-* and *N-*sulfonylaziridines with heterocumulenes. *Chem. Eur. J.* 2014, *20*, 4806–4813. (b) Hooghe, M. D; Waterinckx, A.; De Kimpe, N. D. A novel entry toward 2-Imino-1,3-thiazolidines and 2-Imino-1,3-thiazolines by ring transformation of 2-(thiocyanomethyl)aziridines. *J. Org. Chem.* 2005, *70*, 227–232. (c) Vetica, F.; Pelosi, A.; Gambacorta, A.; Loreto, M. A.; Miceli, M.; Gasperi T., Regioselective 2-imino-1,3-thiazolidine *vs.* 2-imino-1,3-oxazolidine formation from the vicinal sec-amino alcohol of desosamine. *Eur. J. Org. Chem.* 2013, 4666–4673.
- (8) Shen, G.; Lv, X.; Bao, W. Synthesis of *N*-substituted-2-aminobenzo-thiazoles by ligandfree copper(I)-catalyzed cross-coupling reaction of 2-haloanilines with isothiocyanates. *Eur. J. Org. Chem.* 2009, 5897–5901.

- (9) Piscitelli, F.; Ballatore, C.; Smith III, A. B. Solid phase synthesis of 2aminobenzothiazoles. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 644–648.
- (10) Ferreiraa, M.; Sa, M. M. Formal [3+2] annulation involving allylic bromides and thioureas. synthesis of 2-iminothiazolidines through a base-catalyzed intramolecular antimichael addition. *Adv. Synth. Catal.* 2015, *357*, 829–833.
- (11)(a) Ranjan, A.; Mandal, A.; Yerande, S. G.; Dethe, D. H. An asymmetric alkynylation/hydrothiolation cascade: an enantioselective synthesis of thiazolidine-2-imines from imines, acetylenes and isothiocyanates. *Chem. Commun.* 2015, *51*, 14215–14218. (b) Ranjan, A.; Deore, A. S.; Yerande, S. G.; Dethe, D. H. Thiol–yne coupling of propargylamine under solvent-free conditions by bond anion relay chemistry: an efficient synthesis of thiazolidin-2-ylideneamine. *Eur. J. Org. Chem.* 2017, 4130–4139.
- (12) (a) Saunthwal, R. K.; Patel, M.; Tiwari, R. K.; Parang, K.; Verma, A. K. On water: catalyst-free chemoselective synthesis of highly functionalized tetrahydroquinazolines from 2-aminophenylacrylate. *Green Chem.* 2015, *17*, 1434–1441. (b) Saunthwal, R. K.; Patel, M.; Danodia, A. K.; Verma, A. K. Pd-catalyzed Heck-conjoined amidation and concomitant chemoselective Michael-addition: An efficient tandem approach to highly functionalized tetrahydroquinazolines from *o*-haloanilines. *Org. Biomol. Chem.* 2015, *13*, 1521–1530.
- (13) (a) Modi, A.; Sau, P.; Patel, B. K. Base-promoted synthesis of quinoline-4(1*H*)-thiones from *o*-Alkynylanilines and aroyl isothiocyanates. *Org. Lett.* 2017, *19*, 6128–6131. (b) Ali, W.; Dahiya A.; Pandey, R. Alam, T. Patel, B. K. Microwave-assisted cascade

 strategy for the synthesis of indolo[2,3-b]quinolines from 2-(Phenylethynyl)anilines and aryl isothiocynates. *J. Org. Chem.* **2017**, *82*, 2089–2096.

- (14) (a) Mishra, P. K.; Verma, A. K. Metal-free regioselective tandem synthesis of diversely substituted benzimidazo-fused polyheterocycles in aqueous medium. *Green Chem.* 2016, *18*, 6367–6372. (b) Pal, S.; Choudhary, D.; Jainth, M.; Kumar, S.; Tiwari, R. K.; Verma, A. K. Regio- and stereoselective tandem synthesis of oxazolo fused pyridoindoles and benzofurooxazolo pyridines from *o*-alkynylaldehydes. *J. Org. Chem.* 2016, *81*, 9356–9371. (c) Verma, A. K.; Choudhary, D.; Saunthwal, R. K.; Rustagi, V.; Patel, M.; Tiwari, R. K. On water: silver-catalyzed domino approach for the synthesis of benzoxazine/oxazine fused isoquinolines and naphthyridines from *ortho*-alkynylaldehydes. *J. Org. Chem.* 2013, *78*, 6657–6669.
- (15)Crystallographic data for compounds 4c, 4d and 5e have been deposited with the Cambridge Crystallographic Data Centre. CCDC deposit number for compounds 4c, 4d, and 5e are 1845651, 1845650 and 1845652 respectively, contains all crystallographic details of this publication and is available free of charge at www.ccdc.cam.ac.uk.
- (16)(a) Ranjan, A.; Yerande, R.; Wakchaure, P. B.; Yerande, S. G.; Dethe, D. H. Base-mediated hydroamination of propargylamine: a regioselective intramolecular 5-exo-dig cycloisomerization en route to imidazole2-thione. *Org. Lett.* 2014, *16*, 5788–5791. (b) Ding, Q.; Wu, J. A facile route to 2,4-dihydro-1*H*-benzo[*d*][1,3]thiazines *via* silver-catalyzed tandem addition-cyclization reactions *J. Comb. Chem.* 2008, *10*, 541–545. (c) Zhao, P.; Liao, Q.; Gao, H.; Xi, C. Protonated DBU as catalyst for cascade addition-

cyclization of 2-alkynylaniline and carbon disulfide. *Tetrahedron Lett.* **2013**, *54*, 2357–2361.